PioLigOn
Private Company
Funding information not available
Overview
PioLigOn is a private, pre-revenue platform and services company founded in 2017, focusing on computational peptide drug discovery. Its proprietary VPDesigner42™ algorithm is positioned as the first in silico method to design peptides containing nonstandard amino acids, aiming to bridge the 'undruggable target' gap between small molecules and biologics. The company's service model promises to deliver high-affinity (nM to pM) peptide hits within days, significantly accelerating early-stage discovery while drastically reducing material waste. PioLigOn seeks partnerships with larger biopharma entities to diversify drug pipelines with its novel peptide class.
Technology Platform
VPDesigner42™, a proprietary computer algorithm for de novo design of peptides containing nonstandard amino acids, integrated with in-house synthesis and biophysical validation services.
Opportunities
Risk Factors
Competitive Landscape
PioLigOn competes with other computational peptide/protein design companies like Pepticom, Cyrus Biotechnology, and the peptide divisions of larger AI-driven firms (e.g., Insilico Medicine). It also competes with traditional CROs offering peptide discovery services and large biopharma companies developing internal computational platforms. Its differentiator is the specific focus on nonstandard amino acids and a claimed fully integrated, rapid service.